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MODIFIED LUCIFERASE
1
US 7,183,092 B2
CROSS-REFERENCE TO RELATED 
APPLICATIONS
This application claims the benefit of U.S. Provisional 
Application No. 60/508,458, filed Oct. 3, 2003, which is 
incorporated herein by reference.
FIELD OF THE INVENTION
Toxicity testing of industrial chemicals is becoming an 
increasing priority for many chemical manufacturers. How­
ever, obtaining toxicity data using whole animal models is 
expensive, time consuming, and increasingly being per­
ceived as cruel and unethical. Numerous institutions and 
researchers have been working towards developing and 
validating reliable and robust in vitro methods for evaluating 
acute toxicity. Although it may not be feasible to completely 
replace whole animal studies with in vitro methods, progress 
has been significant and several in vitro methods are close to 
being validated internationally.
Viable cells maintain a strictly regulated concentration of 
internal ATP. The cytotoxicity of chemicals can be assessed 
by measuring the ATP concentrations in treated and 
untreated cells. Luciferase is a very sensitive and accurate 
measure of ATP concentration in cells. Luciferase catalyzes 
the oxidation of its substrate, D-luciferin, in the presence of 
ATP, Mg2+ and molecular oxygen, emitting light with a 
quantum yield of 0.88.
The reaction scheme is as follows:
MgATP+D-luciferin+Luciferase(E)±^E-luciferyl-
adenylate+PPz-E-luciferyl-adenylate+02-»E+
MgAMP+C02+oxyluciferin+light
The bioluminescence reaction catalyzed by luciferase 
covers a wide range of applications. Luciferase is actively 
used in the detection of microorganisms, in genetic reporter 
assays, and cytotoxicity measurements during drug discov­
ery.
Despite many applications, wild type firefly luciferase of 
Photinus pyralis has shown limitations due to its instability. 
One of the limitations of luciferase is inhibition of the 
enzyme reaction by chemicals commonly used in an ATP 
assay. This inhibition has contributed to limited applications 
of luciferase for high production volume (HPV) chemical 
testing. Chloroform (CHC13) is one HPV chemical that 
inhibits wild type luciferase activity significantly.
Previously, several research teams have successfully used 
random mutagenesis and screening to isolate mutants of 
luciferase from different species of fireflies. Kajiyama and 
Nakano showed that single amino acid replacements on 
luciferase from Japanese fireflies, Luciola Cruciata and 
Luciola Laterali can have an effect on thermostability or on 
the wavelength of the light emitted. [N. Kajiyama and E. 
Nakano (1991) Prot. Eng. 4, 691-693 and N. Kajiyama and 
E. Nakano (1993) Biochemistry 32, 13795-13799, both 
references incorporated herein by reference.] Peter White 
and David Squirrell also used random mutagenesis to create 
a thermostable mutant luciferase. [P. J. White, D. J. Squir­
rell, P. Amaud, C. R. Lowe, and A. H. Murray (1996) 
Biochem. J. 319, 343-350, incorporated herein by refer­
ence.]
The present invention is directed towards mutating the 
polynucleotide sequence which codes for luciferase to create 
a modified luciferase resistant to inhibition by the test 
chemicals and testing toxicity of HPV chemicals.
SUMMARY OF THE INVENTION
The invention comprises modified luciferase proteins 
which are more resistant to inhibition by test chemicals than 
wild type luciferase. The modified luciferases also contain 
greater thermostability than wild type luciferase. The modi­
fied luciferases also exhibit high activity at elevated pH (up 
to pH 11) under conditions which completely inhibit wild 
type luciferase. These improved enzyme characteristics can 
lead to a wider range of applications for in-vitro cytotoxicity 
screening in drug discovery and devleopment and toxicity 
testing of high production volume chemicals. The modified 
luciferases are more active than wild type luciferase in the 
absence of the stabilizing agent DTT (dithiothreitol) and 
may have benefits in applications where passport proteins 
are used in gene reporter assays.
In one aspect of the invention, a modified luciferase is 
provided in which the amino acid sequence of the luciferase 
differs from wild type luciferase in that serine is replaced by 
threonine at amino acid 239. In another aspect of the 
invention a modified luciferase is provided in which the 
amino acid sequence of the luciferase differs from wild type 
luciferase in that alanine is replaced by threonine at amino 
acid number 532.
In yet another aspect of the invention a modified 
luciferase is provided in which the amino acid sequence of 
the luciferase differs from wild type luciferase in that serine 
is replaced by threonine at amino acid 239, and alanine is 
replaced by threonine at amino acid number 532. In still 
another aspect of the invention a modified luciferase is 
provided in which the amino acid sequence of the luciferase 
differs from wild type luciferase in that serine is replaced by 
threonine at amino acid 239, aspartic acid is replaced by 
tyrosine at amino acid 357 and alanine is replaced by 
threonine at amino acid number 532.
The invention also comprises a fusion protein which 
contains the modified luciferase.
The present invention also comprises polynucleotides 
which encode the modified luciferases, and vectors contain­
ing these polynucleotides. Host cells transformed by the 
vectors are also contemplated by the invention.
The invention also contemplates a method of selecting a 
modified luciferase polypeptide which exhibits greater 
activity in the presence of a chemical than wild type 
luciferase. The method comprises obtaining a polynucle­
otide which encodes wild type luciferase. Random mutagen­
esis is performed on the wild type polynucleotide to create 
a library of multiple modified luciferase polypeptides. The 
activity of each of the multiple modified luciferase polypep­
tides is tested in the presence of a chemical. A modified 
luciferase polypeptide which exhibits greater activity in the 
presence of the chemical than wild type luciferase is 
selected. Suitably such chemicals include chloroform, etha­
nol, methylene chloride, toluene, hexane, xylene, heptane 
and hexane.
Other advantages and a fuller appreciation of specific 
adaptations, compositional variations, and physical 
attributes will be gained upon an examination of the fol­
lowing detailed description of preferred embodiments, taken 
in conjunction with the appended claims.
BRIEF DESCRIPTION OF DRAWINGS
FIG. 1 is a plot showing the effect of increasing concen­
tration of chloroform on wild type luciferase and 
CNBLuc03-02 luciferase (SEQ ID NO: 2) activity.
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FIG. 2 is a plot showing the stability of CNBLuc03-02 
luciferase (SEQ ID NO: 2) over wild type luciferase in the 
presence of 10% Ethanol and 0.5% of various solvents.
FIG. 3 is a plot showing the effect of higher concentration 
of chloroform, methylene chloride and toluene on wild type 
luciferase and CNBLuc03-06 luciferase (SEQ ID NO: 4) 
activity.
FIG. 4 is a plot comparing the activities of wild type 
luciferase and CNBLuc03-06 luciferase (SEQ ID NO: 4) in 
the presence of increasing concentration of non-ionic deter­
gent, Triton X-100.
FIG. 5 is a plot showing the effect of an anionic deteigent, 
SDS on wild type luciferase and CNBLuc03-06 luciferase 
(SEQ ID NO: 4) activities.
FIG. 6 is a plot comparing the activities of wild type 
luciferase and CNBLuc03-06 luciferase (SEQ ID NO: 4) 
kept at a temperature of 0° C. over time.
FIG. 7 is a plot comparing the activities of wild type 
luciferase and CNBLuc03-06 luciferase (SEQ ID NO: 4) 
kept at a temperature of 25° C. over time.
FIG. 8 is a plot comparing the activities of wild type 
luciferase and CNBLuc03-06 luciferase (SEQ ID NO: 4) 
kept at a temperature of 37° C. over time.
FIG. 9 plots wild type luciferase and CNBLuc03-06 
luciferase (SEQ ID NO: 4) activity at different pHs.
Before the embodiments of the invention are explained in 
detail, it is to be understood that the phraseology and 
terminology used herein are for the purpose of description 
and should not be regarded as limiting. The use of “includ­
ing”, “having” and “comprising” and variations thereof 
herein is meant to encompass the items listed thereafter and 
equivalents thereof as well as additional items and equiva­
lents thereof.
DETAILED DESCRIPTION OF THE 
INVENTION
The invention comprises modified luciferase proteins 
which are more resistant to inhibition by test chemicals than 
wild type luciferase. Such test chemicals include HPV 
chemicals. HPV chemicals include chloroform, toluene, 
ethanol, dichloromethane, hexane, 1,4 dimethylbenzene, 
heptane, methylene chloride, sodium dodecyl sulfate, 1,2- 
dichloroethane, chloroethene, ethylbenzene, styrene, cyclo­
hexane, (l-methylethyl)-benzene, nonene, 1,2 dimethylben­
zene, 1,1,1-trichloroethane, diethylbenzene, 1,1- 
dichloroethane, 3,4-dichloro-l-butene, chlorobenzene, 1,1, 
2-trichloroethane, 1-octene, 1-decene, naphthalene and 
chloroethane.
The modified luciferases also contain greater thermosta­
bility than wild type luciferase. The modified luciferases 
also exhibit high activity at elevated pH (up to pH 11) under 
conditions which completely inhibit wild type luciferase. 
The modified luciferases are also more active than wild type 
luciferase in the absence of the stabilizing agent DTT 
(dithiothreitol).
The term “wild type” luciferase refers to the amino acid 
sequence of luciferase of the species Photinus pyralis (SEQ 
ID NO: 6). One polynucleotide which codes for the wild 
type luciferase is SEQ ID NO: 5.
In one aspect of the invention a modified luciferase SEQ 
ID NO: 2 is provided in which the amino acid sequence of 
the luciferase differs from wild type luciferase in that serine 
is replaced by threonine at amino acid 239, and alanine is 
replaced by threonine at amino acid number 532. In another 
aspect, the invention provides a modified luciferase of SEQ 
ID NO: 4. The luciferase of SEQ ID NO. 4 differs from wild
3
type luciferase (SEQ ID NO: 6) in that serine is replaced by 
threonine at amino acid 239, aspartic acid replaced by 
tyrosine at amino acid 357 and alanine is replaced by 
threonine at amino acid number 532.
In a further embodiment the modified luciferases (SEQ ID 
NO: 2 and SEQ ID NO: 4) may be in the form of fusion 
proteins or incorporate polypeptide extensions. This may 
improve the ease by which they can be produced, localized 
in vivo or extracted and purified.
In another aspect of the invention the invention comprises 
a polynucleotide which encodes the modified luciferase SEQ 
ID NO: 2. Suitably this polynucleotide sequence comprises 
SEQ ID NO: 1. The invention also comprises a polynucle­
otide which encodes the modified luciferase SEQ ID NO: 4. 
Suitably this polynucleotide sequence comprises SEQ ID 
NO: 3.
The invention also comprises a polynucleotide sequence 
which contains a region which encodes either the modified 
luciferase SEQ ID NO: 2 or the modified luciferase of SEQ 
ID NO: 4.
The invention also comprises vectors comprising a poly­
nucleotide which encodes, or has a region which encodes, 
for either the modified luciferase SEQ ID NO: 2 or the 
modified luciferase of SEQ ID NO: 4. The vectors can 
include a replication element which permits replication of 
the vector in a suitable host cell and/or a promoter element 
which permits expression of said polynucleotide in a suit­
able host cell. In another aspect of the invention, the 
invention comprises a host cell containing, or transformed 
with, a vector of the invention.
The present invention is further explained by the follow­
ing examples which should not be construed by way of 
limiting the scope of the present invention.
EXAMPLE 1
Creation of Mutated Luciferases
A. Creation of Template
Gateway Technology PCR Cloning System from Invitro- 
gen was used to subclone the Luc gene from pGEM-Luc 
(Promega) (gene for luciferase of Photinus pyralis into a 
Histidine-tag vector, pDEST17. The nucleotide sequence of 
the luc gene is SEQ ID NO: 5. The polypeptide sequence of 
the product of the luc gene is SEQ ID NO: 6. Gateway 
Technology uses the bacteriophage lambda site-specific 
recombination system. This system facilitates the integration 
of lambda into the E-coli chromosome and the switch 
between the lytic and lysogenic pathways (Invitrogen Gate­
way). Gateway Technology is composed of two recombina­
tion reactions: the BP reaction for creating the entry clone 
(DONR201+Luc) and the LR reaction to generate the des­
tination clone (pDEST17+Luc). After the BP reaction, the 
luc gene has L attachment sites for the LR reaction. However 
once the LR reaction is performed the luc gene gains back 
B attachment sites.
PCR fragment luc gene with B attachments was first 
subcloned into pDOR201 by the BP recombination reaction. 
The entry vector then was transformed into competent 
E-Coli, DH5a cells (invitrogen), plated on LB agar+30 
pg/ml kanamycin plates and grown overnight. The purified 
plasmid from DH5a cells containing entry vector was used 
in second recombination reaction, LR reaction. LR reaction 
product was then transformed into competent E-Coli, DH5a 
cells and plated on LB agar+100 pg/ml ampicillin plates for
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overnight growth. The destination vector (pDEST17+luc) 
had an ampicillin resistant gene to avoid contamination by 
the entry vector.
B. First Generation Random Mutagenesis—Creation of 
CNBLuc03-02
The GeneMorph™ PCR Mutagenesis Kit from Stratagene 
was used for random mutagenesis of luciferase. The plasmid 
pDONR201 containing the Luc gene was used as a template 
for error-prone PCR amplification. The oligonucleotide 
primers designed to produce PCR fragments with attach­
ment L sites were used in order to proceed to LR recombi­
nation reaction directly after PCR.
The mutagenized plasmid (pDEST17+mutant Luc) was 
initially transformed into competent E. coli DE15a cells 
(invitrogen). The entire mutant luciferase library was pre­
served by purifying plasmids from scraped cells of all 
transformation plates using Qiagen MiniPrep plasmid puri­
fication kit.
(i) Qualitative Screening of Colonies
1 pi of purified plasmid (-80 ng/pl) containing mutant 
luciferase was used for transformation into competent E. 
coli, BL21 (DE3) cells for better expression level. 40 plates 
(LB agar with 100 pg/ml ampicillin) containing approxi­
mately 150 colonies per plate were generated from each 
transformation. Plates were sealed and stored at 4° C. for at 
least two days before screening.
For primary screening, cells from each transformation 
plate were first transferred onto nitrocellulose membranes. 
Nitrocellulose membranes containing transferred colonies 
were placed on filter paper soaked with screening solution 
consisting of 0.5 mM D-luciferin, 10% (vol.) Ethanol, 5% 
(vol.) Chloroform and 40 mM Tris-Acetate buffer, pFl 5.5, 
colonies facing up, in a Petri-dish. The low pFl condition is 
to aid in the transport of D-luciferin across the cell wall 
during screening. Ethanol is present as a co-solvent to 
solubilize chloroform. Co-solvents are often used for in vitro 
assays, for either ATP detection or other assays using dif­
ferent endpoints. After incubating the membrane the biolu­
minescence was detected with X-ray film using Kodak 
X-omat processor model 1000A, exposure time being not 
more than 30 seconds. The colonies emitting the brightest 
light were selected for secondary screening. Approximately 
400 colonies out of 6000 were selected from primary 
screening.
For secondary screening, selected colonies were grown 
overnight in 200 pi LB broth with 100 pg/ml ampicillin in 
52 wells of a deep/clear 96-well plate overnight at 30° C. 
Two copies of bacterial cells grown in 96-well plates were 
generated using a sterilized metal pin replicator on LB 
agar+100 pg/ml ampicillin plates. Cells were grown at 30°
C. overnight. One copy was used for secondary screening in 
the same manner as in primary screening, leaving the other 
copy for inoculation of selected mutants. After the second­
ary screening of 400 colonies, about 50 colonies were 
selected for final in vitro luciferase activity assay.
(ii) Quantitative In vitro Screening and Selection of Mutants
Selected colonies from secondary screening were inocu­
lated and grown in 5 ml LB broth containing 100 pg/ml 
ampicillin at 30° C. overnight. When the OD660 reached 
approximately 1, bacterial cells were harvested from 1.5 ml 
of culture by centrifugation for 3 min at 12,000 rpm (Eppen- 
dorf centrifuge model 5415D). Flarvested cells were resus­
pended in 1 ml of 40 mM Tris-Acetate buffer, pFl 7.8, and 
sonicated for 10 seconds using a Branson Sonifer 450, Duty 
cycle-40 and output control-4. The activity of each
5
luciferase sample, prepared using 10 pi of supernatant from 
a subsequent centrifugation of sonicated bacterial cell cul­
ture, was tested in 200 pi total reaction volume by a 
Luminometer (Perkin Elmer, model Victor II). Each assay 
contained 40 mM Tris-Acetate, 1 mM MgS04, 0.1 mM 
EDTA (ethylenediaminetetraacetic acid), 33 mM DTT 
(dithiothreitol), 500 pM D-Luciferin, 10% Ethanol and 500 
pM ATP at pFl 7.8. Some screening assays also contained 
68.8 mM chloroform (0.8% vol.).
Different mutant luciferases were compared quantita­
tively by determining the percentage (%) inhibition of 
luciferase activity in the presence of chloroform relative to 
a control without chloroform. The specific activities of 
chloroform-tolerant mutants were generally lower as com­
pared to wild type. Of two isolated colonies with high 
tolerance to chloroform treatment, a mutant that had com­
parable activity and was inhibited much less by chloroform 
(CNBLuc03-02) was finally obtained. The nucleotide 
sequence of CNBLuc03-02 is SEQ ID No: 1. The polypep­
tide sequence of the product of SEQ ID No: 1 is SEQ ID No: 
2 .
C. Second Generation Random Mutagenesis—Creation of 
CNBLuc03-06.
The general protocol for second generation random 
mutagenesis, including transformation and screening proto­
cols, was essentially the same as for the first generation of 
random mutagenesis, as described in Section B of this 
example, with an exception of the template. The intermedi­
ate mutant luciferase gene (CNBLuc03-02, SEQ ID NO: 1) 
from the first random mutagenesis was used as a template. 
The intermediate mutant in pDEST17 vector had B attach­
ment sites resulting from a previous LR reaction. Two new 
adaptor primers designed for B attachment sites were used 
for error-prone PCR amplification.
The new library, PCR fragments with B attachment sites, 
was used for the BP recombination reaction. The entry 
clone, pDONR201, containing the second generation mutant 
luc genes, was transformed into competent E-Coli, DF15a 
cells. These cells were plated on LB agar+30 pg/ml kana- 
mycin plates for overnight growth. Plasmids from all the 
scraped colonies were purified and used for the LR recom­
bination reaction.
Finally, pDEST17, containing second generation mutant 
luc genes, was transformed into competent E-Coli, DF15a 
cells. After screening the library generated from second 
generation random mutagenesis, a mutant luciferase, 
CNBLuc03-06, was obtained that was not only resistant to, 
but also had the capacity to be activated by chloroform. The 
nucleotide sequence of CNBLuc03-06 is SEQ ID NO: 3. 
The polypeptide sequence of the product of SEQ ID NO: 3 
is SEQ ID NO: 4.
EXAMPLE 2
Stability of CNBLuc03-02 Luciferase in the 
Presence of Potential Inhibitors
The stability of CNBLuc03-02 luciferase (SEQ ID NO: 2) 
in the presence of a range of potential inhibitors was 
assayed. The basic assay contained 40 mM Tris-Acetate at 
pH 7.8, 1 mM MgS04, 0.1 mM EDTA (ethylenediamine­
tetraacetic acid), 500 pM D-Luciferin and 500 pM ATP. 
Ethanol, DTT (dithiothreitol) and potential inhibitors were 
included at the concentrations stated.
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A. Stability Of CNBLuc03-02 in the Presence of Chlorform
In the presence of 5% ethanol, 33 mM DTT and 0.8%
chloroform, CNBLuc03-02 luciferase (SEQ ID NO: 2) from 
10 pi cell lysates showed only about a 30% inhibition by 
0.8% CHC13 whereas the wild type luciferase was inhibited 
over 80% in the same condition. FIG. 1 shows that 10 pi cell 
lysates containing CNBLuc03-02 luciferase (SEQ ID NO: 2) 
assayed at different concentrations of chloroform in the 
presence of 33 mM DTT and 5% ethanol were found to 
maintain 80% of the original activity, whereas wild-type 
luciferase was reduced to about 20% of the original activity 
under the same conditions.
B. Stability of CNBLuc03-02 Luciferase in the Presence of 
Eligh Production Volume Chemicals
Five different F1PV solvents (CF12C12, toluene, hexane, 
xylene, and heptane), known to inhibit wild-type luciferase 
activity, were selected to demonstrate the stability of 
CNBLuc03-02 luciferase (SEQ ID NO: 2). FIG. 2 shows 
that in the presence of 0.5% of each selected solvent, 33 mM 
DTT and 10% ethanol, CNBLuc03-02 luciferase (SEQ ID 
NO: 2) activity from 10 pi cell lysate was not inhibited as 
much as wild-type luciferase from 10 pi cell lysate, and 
CNBLuc03-02 luciferase (SEQ ID NO: 2) activity was not 
inhibited more than 15%, except when tolulene was present. 
Toluene inhibited CNBLuc03-02 luciferase (SEQ ID NO: 2) 
activity by approximately 40% and wild type luciferase 
activity by approximately 80%.
EXAMPLE 3
Stability of CNBLuc03-06 Luciferase in the 
Presence of Potential Inhibitors
The stability of CNBLuc03-06 luciferase (SEQ ID NO: 
4), both in purified form and in cell lysates, in the presence 
of a range of potential inhibitors was assayed. The basic 
assay contained 40 mM Tris-Acetate at pFl 7.8, 1 mM 
MgS04, 0.1 mM EDTA (ethylenediaminetetraacetic acid), 
500 pM D-Luciferin and 500 pM ATP. Ethanol, DTT (dithio- 
threitol) and potential inhibitors were included at the con­
centrations stated.
A. Purification of CNBLuc03-06 Luciferase
Purified CNBLuc03-06 luciferase (SEQ ID NO: 4) was 
made by first inoculating 1 L LB broth (100 pg/ml ampi- 
cillin) with E. coli BL21 (DE3) cells containing the 
pDEST17 vector with a Elis-tagged CNBLuc03-06 and 
growing the cells at 30° C. overnight. Cells were then 
induced by IPTG (40 pM) to promote luciferase production 
and cultured for 3 hours. The cells were harvested by 
centrifugation (on sorval model RC5C, rotor SLA-1500, 10 
min 7,000 g, 0-4° C.). Flarvested cells were resuspended in 
50 ml 100 mM Tris-Acetate buffer, pFl 7.8, and sonicated 3 
times for 1 min (sonicated on Branson model sonifer 450, 
output control—6, duty cycle—constant, on ice). The 
soluble fraction obtained after centrifugation was used for 
ammonium sulfate fractionation.
Luciferase was precipitated in the range of 50-70% 
ammonium sulfate. The sample was further purified by 
affinity chromatography using a Nickel Chelating column 
(.Amersham Pharmacia, FliTrap). Steps of 50 mM and 200 
mM of Imidazole were used to wash the column of non­
specific binding proteins. Luciferase was eluted using 500 
mM imidazole, and imidazole was removed from the recov­
ered enzyme using a desalting column (Amersham Pharma­
cia, FliPrep 26/10). The purified luciferase, CNBLuc03-06 
(SEQ ID NO: 4), was analyzed by SDS PAGE Gel-Electro­
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phoresis using a 4-12% precasted using Duramide gel 
(Cambrex Rockland) run at 150 Volts for approximately 40 
minutes. The Coomassie stained gel showed no significant 
contaminants.
B. Stability of CNBLuc03-06 Luciferase in the Presence of 
Eligh Production Volume Chemicals
Using the basic assay and in the presence of 5% ethanol, 
33 mM DTT and 0.8% chloroform, CNBLuc03-06 
luciferase (SEQ ID NO: 4) from cell lysates was found to be 
activated by about 30% compared with the absence of 
chloroform. This effect was confirmed by repeated experi­
ments. With 20 ng purified CNBLuc03-06 luciferase (SEQ 
ID NO: 4) and in the presence of of 2.5% ethanol, 1 mM 
DTT and 86 mM chloroform an activation of approximately 
50% was measured, compared with the absence of chloro­
form.
The capacity of a variety F1PV chemicals to inhibit or 
activate both wild type luciferase and CNBLuc03-06 
luciferase (SEQ ID NO: 4) activity compared to controls 
without F1PV chemicals was tested. Fligher concentrations 
of chloroform (172 mM), methylene chloride (318 mM) or 
toluene (2.7 mM) were used. The basic assay contained 20ng 
of purified CNBLuc03-06, 1 mM DTT and 2.5% ethanol. 
CNBLuc03-06 luciferase (SEQ ID NO: 4) was exposed to 
each chemical for less than 5 minutes before measuring the 
light output. FIG. 3 shows that wild-type was inhibited by 
about 70% compared to controls for both chloroform and 
methylene chloride and was inhibited by about 20% for 
tolulene, whereas CNBLuc03-06 luciferase (SEQ ID NO: 4) 
was activated by approximately 60% for chloroform, acti­
vated by approximately 80% for methylene chloride and 
activated by approximately 20% for tolulene.
C. Stability of CNBLuc03-06 in the Presence of Detergents
The stability of CNBLuc03-06 luciferase (SEQ ID NO: 4)
in the presence of Triton X-100 and SDS was determined 
using 20 ng of purified luciferase per sample using the basic 
assay conditions and in the presence of 0% ethanol and 33 
mM DTT. The effect of detergents on wild type luciferase 
was determined previously by W. J. Simpson and J. R. M. 
Flammond (W. J. Simpson and J. R. M. Flammond, (1991) 
Journal o f Bioluminescence & Chemiluminescence, 6. 
97-106, incorporated herein by reference). They reported 
the anionic detergents inhibit luciferase activity, and cationic 
detergents and nonionic detergents increase the reaction rate 
when the concentration of detergent exceeds critical micelle 
concentration (CMC) value but only up to certain concen­
trations. As expected both wild type luciferase and 
CNBLuc03-06 luciferase (SEQ ID NO: 4) were activated by 
the nonionic detergent, Triton X-100, up to final concentra­
tion of 1.25% in the reaction.
FIG. 4 shows that wild type luciferase activity increased 
until 1.25% then it started decreasing as Triton X-100 
concentration increased up to 5%. For CNBLuc03-06 
luciferase (SEQ ID NO: 4) activity showed a similar trend 
as wild type luciferase, but maintained activities above the 
control at all concentrations of Triton X-100.
SDS was used for testing the effect of anionic detergents. 
FIG. 5 shows that even small concentrations of SDS inhib­
ited luciferase activity significantly for both wild type 
luciferase and CNBLuc03-06 luciferase. Flowever, 
CNBLuc03-06 luciferase (SEQ ID NO: 4) retained much 
more activity at all concentrations of SDS compared to wild 
type luciferase.
8
5
10
15
20
25
30
35
40
45
50
55
60
65
9
EXAMPLE 4
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Thermostability of CNBLuc03-06 Luciferase
Both purified wild type luciferase and CNBLuc03-06 
luciferase (SEQ ID NO: 4) were diluted to 10 pg/ml and 
aliquoted in three micro-centrifuge tubes for these storage 
stability studies conducted at different temperatures. The 
tubes containing wild type luciferase and CNBluc03-06 
luciferase (SEQ ID NO: 4) were incubated at three different 
temperatures, 0° C. (FIG. 6), 25° C. (FIG. 7), and 37° C. 
(FIG. 8) overtime. The assay contained 40 mM Tris-Acetate 
at pH 7.8, 1 mM MgS04, 0.1 mM EDTA, 500 pM D-Lu- 
ciferin, 1 mM ATP, 0% ethanol and 33 mM DTT. The light 
output was measured every 30 minutes after two initial 
measurements at time 0 and 10 minutes. For each measure­
ment all the samples were diluted to 2  pg/ml so that 1 0  pi of 
each sample could be added to give 2 0  ng of purified enzyme 
in each reaction.
At all three temperatures (0° C., 25° C., and 37° C.) 
CNBLuc03-06 luciferase (SEQ ID NO: 4) retained more 
activity than wild type luciferase. This shows that 
CNBLuc03-06 luciferase (SEQ ID NO: 4) has improved 
enzymatic properties of wild type luciferase in many aspects 
and is more stable than wild type luciferase to general 
denaturation.
EXAMPLE 5
pH Shift of CNBLuc03-06 Luciferase
CNBLuc03-06 luciferase (SEQ ID NO: 4) exhibits high 
activity at elevated pH (up to pH 11) under conditions which 
completely inhibit wild type luciferase. These improved 
enzyme characteristics can lead to a wider range of appli­
cations for in-vitro cytotoxicity screening in drug discovery 
and devleopment and toxicity testing of high production 
volume chemicals.
FIG. 9 demonstrates the difference in optimum pH for 
wild type luciferase and CNBLuc03-06 luciferase (SEQ ID 
NO: 4). 20 ng of enzyme was used for each reaction. The pH 
was maintained at 7.8 by 40 mM Tris-acetate buffer and 33 
mM DTT was added to each reaction. Both substrates, 
MGATP and D-Luciferin were saturated at 1 mM and 500 
pM respectively. The values were normalized against the
highest RLU (relative light units) at each pH optimum for 
comparison purpose. CNBLuc03-06 luciferase (SEQ ID 
NO: 4) has optimum pH of 9, but the high enough activity 
is retained at lower pHs in which enables us to use this 
5 mutant luciferase in case a wide range of pH is required for 
the assay (between 8- 11).
EXAMPLE 6
io DTT Effect of CNBLuc03-06 Luciferase
Dithiothreitol (DTT) is an enzyme stabilizing agent used 
to reduce disulfide bonds (break the bonds) that are not 
normally formed under physiological conditions. Both puri- 
15 tied wild type luciferase and CNBLuc03-06 luciferase (SEQ 
ID NO: 4) were diluted to 2 pg/ml in 40 mM Tris Acetate 
buffer at pH 7.8. The assay contained 40 mM Tris-Acetate 
at pH 7.8, 1 mM MgS04, 0.1 mM EDTA, 500 pM D-Lu- 
ciferin, 1 mM ATP, and 0 mM DTT. The light output was 
20 measured over time and three replicate measurements were 
made for each luciferase. The average value of the highest 
light output reading obtained over time was used to deter­
mine specific activity of each enzyme.
CNBLuc03-06 luciferase (SEQ ID NO: 4) exhibited much 
25 higher activity (9.6±0.4xl09 RLU/mg enzyme/sec) com­
pared to wild type luciferase (2.9±1.6xl09 RLU/mg enzyme/ 
sec). These results show that CNBLuc03-06 luciferase (SEQ 
ID NO: 4) has improved activity in applications when DTT 
would interfere in assay performance, and may be of benefit 
30 in applications when luciferase is carried into cells with a 
passport protein in gene reporter assays.
While the present invention has now been described and 
exemplified with some specificity, those skilled in the art 
will appreciate the various modifications, including varia- 
35 tions, additions, and omissions, that may be made in what 
has been described. Accordingly, it is intended that these 
modifications also be encompassed by the present invention 
and that the scope of the present invention be limited solely 
by the broadest interpretation lawfully accorded the 
40 appended claims.
All patents, publications and references cited herein are 
hereby fully incorporated by reference. In case of conflict 
between the present disclosure and incorporated patents, 
publications and references, the present disclosure should 
control.
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SEQUENCE LISTING
<160> NUMBER OF SEQ ID NOS: 6
<210> SEQ ID NO 1 
<211> LENGTH: 1650 
<212> TYPE: DNA
<213> ORGANISM: Photinus pyralis 
<400> SEQUENCE: 1
atggaagacg ccaaaaacat aaagaaaggc ccggcgccat tctatcctct agaggatgga 60
accgctggag agcaactgca taaggctatg aagagatacg ccctggttcc tggaacaatt 120
gcttttacag atgcacatat cgaggtgaac atcacgtacg cggaatactt cgaaatgtcc 180
gttcggttgg cagaagctat gaaacgatat gggctgaata caaatcacag aatcgtcgta 240
tgcagtgaaa actctcttca attctttatg ccggtgttgg gcgcgttatt tatcggagtt 300
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gcagttgcgc ccgcgaacga catttataat gaacgtgaat tgctcaacag tatgaacatt 360
tcgcagccta ccgtagtgtt tgtttccaaa aaggggttgc aaaaaatttt gaacgtgcaa 420
aaaaaattac caataatcca gaaaattatt atcatggatt ctaaaacgga ttaccaggga 480
tttcagtcga tgtacacgtt cgtcacatct catctacctc ccggatttaa tgaatacgat 540
tttgtaccag agtcctttga tcgtgacaaa acaattgcac tgataatgaa ttcctctgga 600
tctactgggt tacctaaggg tgtggccctt ccgcatagaa ctgcctgcgt cagattctcg 660
catgccagag atcctatttt tggcaatcaa atcattccgg atactgcgat tttaactgtt 720
gttccattcc atcacggttt tggaatgttt actacactcg gatatttgat atgtggtttt 780
cgagtcgtct taatgtatag atttgaagaa gagctgtttt tacgatccct tcaggattac 840
aaaattcaaa gtgcgttgct agtaccaacc ctattttcat tcttcgccaa aagcactctg 900
attgacaaat acgatttatc taatttacac gaaattgctt ctgggggcgc acctctttcg 960
aaagaagtcg gcgaagcggt tgcaaaacgc ttccatcttc cagggatacg acaaggatat 1020
gggctcactg agactacatc agctattctg attacacccg agggggatga taaaccgggc 1080
gcggtcggta aagttgttcc attttttgaa gcgaaggttg tggatctgga tactgggaaa 1140
acgctgggcg ttaatcagag aggcgaatta tgtgtcagag gacctatgat tatgtccggt 1200
tatgtaaaca atccggaagc gaccaacgcc ttgattgaca aggatggatg gctacattct 1260
ggagacatag cttactggga cgaagacgaa cacttcttca tagttgaccg cttgaagtct 1320
ttaattaaat acaaaggata tcaggtggcc cccgctgaat tggaatcgat attgttacaa 1380
caccccaaca tcttcgacgc gggcgtggca ggtcttcccg acgatgacgc cggtgaactt 1440
cccgccgccg ttgttgtttt ggagcacgga aagacgatga cggaaaaaga gatcgtggat 1500
tacgtcgcca gtcaagtaac aaccgcgaaa aagttgcgcg gaggagttgt gtttgtggac 1560
gaagtaccga aaggtcttac cggaaaactc gacacaagaa aaatcagaga gatcctcata 1620 
aaggccaaga agggcggaaa gtccaaattg 1650
<210> SEQ ID NO 2 
<211> LENGTH: 550 
<212> TYPE: PRT
<213> ORGANISM: Photinus pyralis 
<400> SEQUENCE: 2
Met Glu Asp Ala Lys Asn lie Lys Lys Gly Pro Ala Pro Phe Tyr Pro
1 5  10 15
Leu Glu Asp Gly Thr Ala Gly Glu Gin Leu His Lys Ala Met Lys Arg
20 25 30
Tyr Ala Leu Val Pro Gly Thr lie Ala Phe Thr Asp Ala His lie Glu
35 40 45
Val Asn lie Thr Tyr Ala Glu Tyr Phe Glu Met Ser Val Arg Leu Ala
50 55 60
Glu Ala Met Lys Arg Tyr Gly Leu Asn Thr Asn His Arg lie Val Val
65 70 75 80
Cys Ser Glu Asn Ser Leu Gin Phe Phe Met Pro Val Leu Gly Ala Leu
85 90 95
Phe lie Gly Val Ala Val Ala Pro Ala Asn Asp lie Tyr Asn Glu Arg
100 105 110
Glu Leu Leu Asn Ser Met Asn lie Ser Gin Pro Thr Val Val Phe Val
Ser Lys Lys Gly Leu Gin Lys lie Leu Asn Val Gin Lys Lys Leu Pro
US 7,183,092 B2
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130 135 140
lie lie Gin Lys lie lie lie Met Asp Ser Lys Thr Asp Tyr Gin Gly
145 150 155 160
Phe Gin Ser Met Tyr Thr Phe Val Thr Ser His Leu Pro Pro Gly Phe
165 170 175
Asn Glu Tyr Asp Phe Val Pro Glu Ser Phe Asp Arg Asp Lys Thr lie
180 185 190
Ala Leu lie Met Asn Ser Ser Gly Ser Thr Gly Leu Pro Lys Gly Val
195 200 205
Ala Leu Pro His Arg Thr Ala Cys Val Arg Phe Ser His Ala Arg Asp
210 215 220
Pro lie Phe Gly Asn Gin lie lie Pro Asp Thr Ala lie Leu Thr Val
225 230 235 240
Val Pro Phe His His Gly Phe Gly Met Phe Thr Thr Leu Gly Tyr Leu
245 250 255
lie Cys Gly Phe Ala Val Val Leu Met Tyr Arg Phe Glu Glu Glu Leu
260 265 270
Phe Leu Arg Ser Leu Gin Asp Tyr Lys lie Gin Ser Ala Leu Leu Val
275 280 285
Pro Thr Leu Phe Ser Phe Phe Ala Lys Ser Thr Leu lie Asp Lys Tyr
290 295 300
Asp Leu Ser Asn Leu His Glu lie Ala Ser Gly Gly Ala Pro Leu Ser
305 310 315 320
Lys Glu Val Gly Glu Ala Val Ala Lys Arg Phe His Leu Pro Gly lie
325 330 335
Arg Gin Gly Tyr Gly Leu Thr Glu Thr Thr Ser Ala lie Leu lie Thr
340 345 350
Pro Glu Gly Asp Asp Lys Pro Gly Ala Val Gly Lys Val Val Pro Phe
355 360 365
Phe Glu Ala Lys Val Val Asp Leu Asp Thr Gly Lys Thr Leu Gly Val
370 375 380
Asn Gin Arg Gly Glu Leu Cys Val Arg Gly Pro Met lie Met Ser Gly
385 390 395 400
Tyr Val Asn Asn Pro Glu Ala Thr Asn Ala Leu lie Asp Lys Asp Gly
405 410 415
Trp Leu His Ser Gly Asp lie Ala Tyr Trp Asp Glu Asp Glu His Phe
420 425 430
Phe lie Val Asp Arg Leu Lys Ser Leu lie Lys Tyr Lys Gly Tyr Gin
435 440 445
Val Ala Pro Ala Glu Leu Glu Ser lie Leu Leu Gin His Pro Asn lie
450 455 460
Phe Asp Ala Gly Val Ala Gly Leu Pro Asp Asp Asp Ala Gly Glu Leu
465 470 475 480
Pro Ala Ala Val Val Val Leu Glu His Gly Lys Thr Met Thr Glu Lys
485 490 495
Glu lie Val Asp Tyr Val Ala Ser Gin Val Thr Thr Ala Lys Lys Phe
500 505 510
Arg Gly Gly Val Val Phe Val Asp Glu Val Pro Lys Gly Leu Thr Gly
515 520 525
Lys Leu Asp Thr Arg Lys lie Arg Glu lie Leu lie Lys Ala Lys Lys
530 535 540
Gly Gly Lys Ser Lys Leu
545 550
15
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<210> SEQ ID NO 3 
<211> LENGTH: 1650 
<212> TYPE: DNA
<213> ORGANISM: Photinus pyralis 
<400> SEQUENCE: 3
atggaagacg ccaaaaacat aaagaaaggc ccggcgccat tctatcctct agaggatgga 60
accgctggag agcaactgca taaggctatg aagagatacg ccctggttcc tggaacaatt 120
gcttttacag atgcacatat egaggtgaao atcacgtacg cggaatactt cgaaatgtcc 180
gttcggttgg cagaagctat gaaacgatat gggctgaata caaatcacag aatcgtcgta 240
tgcagtgaaa actctcttca attctttatg ccggtgttgg gcgcgttatt tatcggagtt 300
gcagttgcgc ccgcgaacga catttataat gaacgtgaat tgctcaacag tatgaacatt 360
tcgcagccta ccgtagtgtt tgtttccaaa aaggggttgo aaaaaatttt gaacgtgcaa 420
aaaaaattac caataatcca gaaaattatt atcatggatt ctaaaacgga ttaccaggga 480
tttcagtcga tgtacacgtt cgtcacatct catctacctc ccggatttaa tgaatacgat 540
tttgtaccag agtcctttga tcgtgacaaa acaattgcac tgataatgaa ttcctctgga 600
tctactgggt tacctaaggg tgtggooott ccgcatagaa ctgcctgcgt cagattctcg 660
catgccagag atcctatttt tggcaatcaa atcattccgg atactgcgat tttaactgtt 720
gttccattcc atcacggttt tggaatgttt actacactcg gatatttgat atgtggtttt 780
cgagtcgtct taatgtatag atttgaagaa gagctgtttt tacgatccct tcaggattac 840
aaaattcaaa gtgcgttgct agtaccaacc ctattttcat tcttcgccaa aagcactctg 900
attgacaaat acgatttatc taatttacac gaaattgctt etgggggogo acctctttcg 960
aaagaagtcg gcgaagcggt tgcaaaacgc ttccatcttc eagggataog acaaggatat 1020
gggctcactg agactacatc agctattctg attacacccg agggggatta taaaccgggc 1080
gcggtcggta aagttgttcc attttttgaa gcgaaggttg tggatctgga tactgggaaa 1140
acgctgggcg ttaatcagag aggcgaatta tgtgtcagag gacctatgat tatgtccggt 1200
tatgtaaaca atccggaagc gaccaacgcc ttgattgaca aggatggatg gctacattct 1260
ggagacatag cttactggga cgaagacgaa cacttcttca tagttgaccg cttgaagtct 1320
ttaattaaat acaaaggata tcaggtggcc cccgctgaat tggaatcgat attgttacaa 1380
caccccaaca tcttcgacgc gggcgtggca ggtcttcccg acgatgacgc eggtgaaott 1440
cccgccgccg ttgttgtttt ggagcacgga aagacgatga cggaaaaaga gatcgtggat 1500
tacgtcgcca gtcaagtaac aaccgcgaaa aagttgcgcg gaggagttgt gtttgtggac 1560
gaagtaccga aaggtcttac cggaaaactc gacacaagaa aaatcagaga gatcctcata 1620
aaggccaaga agggcggaaa gtccaaattg 1650
<210> SEQ ID NO 4 
<211> LENGTH: 550 
<212> TYPE: PRT
<213> ORGANISM: Photinus pyralis 
<400> SEQUENCE: 4
Met Glu Asp Ala Lys Asn lie Lys Lys Gly Pro Ala Pro Phe Tyr Pro
1 5  10 15
Leu Glu Asp Gly Thr Ala Gly Glu Gin Leu His Lys Ala Met Lys Arg 
20 25 30
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Tyr Ala Leu Val Pro Gly Thr lie Ala Phe Thr Asp Ala His lie Glu
35 40 45
Val Asn lie Thr Tyr Ala Glu Tyr Phe Glu Met Ser Val Arg Leu Ala
50 55 60
Glu Ala Met Lys Arg Tyr Gly Leu Asn Thr Asn His Arg lie Val Val
65 70 75 80
Cys Ser Glu Asn Ser Leu Gin Phe Phe Met Pro Val Leu Gly Ala Leu
85 90 95
Phe lie Gly Val Ala Val Ala Pro Ala Asn Asp lie Tyr Asn Glu Arg
100 105 110
Glu Leu Leu Asn Ser Met Asn lie Ser Gin Pro Thr Val Val Phe Val
115 120 125
Ser Lys Lys Gly Leu Gin Lys lie Leu Asn Val Gin Lys Lys Leu Pro
130 135 140
lie lie Gin Lys lie lie lie Met Asp Ser Lys Thr Asp Tyr Gin Gly
145 150 155 160
Phe Gin Ser Met Tyr Thr Phe Val Thr Ser His Leu Pro Pro Gly Phe
165 170 175
Asn Glu Tyr Asp Phe Val Pro Glu Ser Phe Asp Arg Asp Lys Thr lie
180 185 190
Ala Leu lie Met Asn Ser Ser Gly Ser Thr Gly Leu Pro Lys Gly Val
195 200 205
Ala Leu Pro His Arg Thr Ala Cys Val Arg Phe Ser His Ala Arg Asp
210 215 220
Pro lie Phe Gly Asn Gin lie lie Pro Asp Thr Ala lie Leu Thr Val
225 230 235 240
Val Pro Phe His His Gly Phe Gly Met Phe Thr Thr Leu Gly Tyr Leu
245 250 255
lie Cys Gly Phe Ala Val Val Leu Met Tyr Arg Phe Glu Glu Glu Leu
260 265 270
Phe Leu Arg Ser Leu Gin Asp Tyr Lys lie Gin Ser Ala Leu Leu Val
275 280 285
Pro Thr Leu Phe Ser Phe Phe Ala Lys Ser Thr Leu lie Asp Lys Tyr
290 295 300
Asp Leu Ser Asn Leu His Glu lie Ala Ser Gly Gly Ala Pro Leu Ser
305 310 315 320
Lys Glu Val Gly Glu Ala Val Ala Lys Arg Phe His Leu Pro Gly lie
325 330 335
Arg Gin Gly Tyr Gly Leu Thr Glu Thr Thr Ser Ala lie Leu lie Thr
340 345 350
Pro Glu Gly Asp Tyr Lys Pro Gly Ala Val Gly Lys Val Val Pro Phe
355 360 365
Phe Glu Ala Lys Val Val Asp Leu Asp Thr Gly Lys Thr Leu Gly Val
370 375 380
Asn Gin Arg Gly Glu Leu Cys Val Arg Gly Pro Met lie Met Ser Gly
385 390 395 400
Tyr Val Asn Asn Pro Glu Ala Thr Asn Ala Leu lie Asp Lys Asp Gly
405 410 415
Trp Leu His Ser Gly Asp lie Ala Tyr Trp Asp Glu Asp Glu His Phe
420 425 430
Phe lie Val Asp Arg Leu Lys Ser Leu lie Lys Tyr Lys Gly Tyr Gin
435 440 445
Val Ala Pro Ala Glu Leu Glu Ser lie Leu Leu Gin His Pro Asn lie
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450 455 460
Phe Asp Ala Gly Val Ala Gly Leu Pro Asp Asp Asp Ala Gly Glu Leu
465 470 475 480
Pro Ala Ala Val Val Val Leu Glu His Gly Lys Thr Met Thr Glu Lys
485 490 495
Glu lie Val Asp Tyr Val Ala Ser Gin Val Thr Thr Ala Lys Lys Phe
500 505 510
Arg Gly Gly Val Val Phe Val Asp Glu Val Pro Lys Gly Leu Thr Gly
515 520 525
Lys Leu Asp Thr Arg Lys lie Arg Glu lie Leu lie Lys Ala Lys Lys
530 535 540
Gly Gly Lys Ser Lys Leu
545 550
<210> SEQ ID NO 5 
<211> LENGTH: 1650 
<212> TYPE: DNA
<213> ORGANISM: Photinus pyralis 
<400> SEQUENCE: 5
atggaagacg ccaaaaacat aaagaaaggc ccggcgccat tctatcctct agaggatgga 60
accgctggag agcaactgca taaggctatg aagagatacg ccctggttcc tggaacaatt 120
gcttttacag atgcacatat egaggtgaao atcacgtacg cggaatactt cgaaatgtcc 180
gttcggttgg cagaagctat gaaacgatat gggctgaata caaatcacag aatcgtcgta 240
tgcagtgaaa actctcttca attctttatg ccggtgttgg gcgcgttatt tatcggagtt 300
gcagttgcgc ccgcgaacga catttataat gaacgtgaat tgctcaacag tatgaacatt 360
tcgcagccta ccgtagtgtt tgtttccaaa aaggggttgo aaaaaatttt gaacgtgcaa 420
aaaaaattac caataatcca gaaaattatt atcatggatt ctaaaacgga ttaccaggga 480
tttcagtcga tgtacacgtt cgtcacatct catctacctc ccggatttaa tgaatacgat 540
tttgtaccag agtcctttga tcgtgacaaa acaattgcac tgataatgaa ttcctctgga 600
tctactgggt tacctaaggg tgtggooott ccgcatagaa ctgcctgcgt cagattctcg 660
catgccagag atcctatttt tggcaatcaa atcattccgg atactgcgat tttaagtgtt 720
gttccattcc atcacggttt tggaatgttt actacactcg gatatttgat atgtggtttt 780
cgagtcgtct taatgtatag atttgaagaa gagctgtttt tacgatccct tcaggattac 840
aaaattcaaa gtgcgttgct agtaccaacc ctattttcat tcttcgccaa aagcactctg 900
attgacaaat acgatttatc taatttacac gaaattgctt etgggggogo acctctttcg 960
aaagaagtcg gcgaagcggt tgcaaaacgc ttccatcttc eagggataog acaaggatat 1020
gggctcactg agactacatc agctattctg attacacccg agggggatga taaaccgggc 1080
gcggtcggta aagttgttcc attttttgaa gcgaaggttg tggatctgga tactgggaaa 1140
acgctgggcg ttaatcagag aggcgaatta tgtgtcagag gacctatgat tatgtccggt 1200
tatgtaaaca atccggaagc gaccaacgcc ttgattgaca aggatggatg gctacattct 1260
ggagacatag cttactggga cgaagacgaa cacttcttca tagttgaccg cttgaagtct 1320
ttaattaaat acaaaggata tcaggtggcc cccgctgaat tggaatcgat attgttacaa 1380
caccccaaca tcttcgacgc gggcgtggca ggtcttcccg acgatgacgc eggtgaaott 1440
cccgccgccg ttgttgtttt ggagcacgga aagacgatga cggaaaaaga gatcgtggat 1500
tacgtcgcca gtcaagtaac aaccgcgaaa aagttgcgcg gaggagttgt gtttgtggac 1560
21
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gaagtaccga aaggtcttac cggaaaactc gacgcaagaa aaatcagaga gatcctcata 
aaggccaaga agggcggaaa gtccaaattg
<210> SEQ ID NO 6 
<211> LENGTH: 550 
<212> TYPE: PRT
<213> ORGANISM: Photinus pyralis
<400> SEQUENCE: 6
Met Glu Asp Ala Lys Asn lie Lys Lys Gly Pro Ala Pro Phe Tyr Pro
1 5 10 15
Leu Glu Asp Gly Thr Ala Gly Glu Gin Leu His Lys Ala Met Lys Arg
20 25 30
Tyr Ala Leu Val Pro Gly Thr lie Ala Phe Thr Asp Ala His lie Glu
35 40 45
Val Asn lie Thr Tyr Ala Glu Tyr Phe Glu Met Ser Val Arg Leu Ala
50 55 60
Glu Ala Met Lys Arg Tyr Gly Leu Asn Thr Asn His Arg lie Val Val
65 70 75 80
Cys Ser Glu Asn Ser Leu Gin Phe Phe Met Pro Val Leu Gly Ala Leu
85 90 95
Phe lie Gly Val Ala Val Ala Pro Ala Asn Asp lie Tyr Asn Glu Arg
100 105 110
Glu Leu Leu Asn Ser Met Asn lie Ser Gin Pro Thr Val Val Phe Val
115 120 125
Ser Lys Lys Gly Leu Gin Lys lie Leu Asn Val Gin Lys Lys Leu Pro
130 135 140
lie lie Gin Lys lie lie lie Met Asp Ser Lys Thr Asp Tyr Gin Gly
145 150 155 160
Phe Gin Ser Met Tyr Thr Phe Val Thr Ser His Leu Pro Pro Gly Phe
165 170 175
Asn Glu Tyr Asp Phe Val Pro Glu Ser Phe Asp Arg Asp Lys Thr lie
180 185 190
Ala Leu lie Met Asn Ser Ser Gly Ser Thr Gly Leu Pro Lys Gly Val
195 200 205
Ala Leu Pro His Arg Thr Ala Cys Val Arg Phe Ser His Ala Arg Asp
210 215 220
Pro lie Phe Gly Asn Gin lie lie Pro Asp Thr Ala lie Leu Ser Val
225 230 235 240
Val Pro Phe His His Gly Phe Gly Met Phe Thr Thr Leu Gly Tyr Leu
245 250 255
lie Cys Gly Phe Ala Val Val Leu Met Tyr Arg Phe Glu Glu Glu Leu
260 265 270
Phe Leu Arg Ser Leu Gin Asp Tyr Lys lie Gin Ser Ala Leu Leu Val
275 280 285
Pro Thr Leu Phe Ser Phe Phe Ala Lys Ser Thr Leu lie Asp Lys Tyr
290 295 300
Asp Leu Ser Asn Leu His Glu lie Ala Ser Gly Gly Ala Pro Leu Ser
305 310 315 320
Lys Glu Val Gly Glu Ala Val Ala Lys Arg Phe His Leu Pro Gly lie
325 330 335
Arg Gin Gly Tyr Gly Leu Thr Glu Thr Thr Ser Ala lie Leu lie Thr
340 345 350
1620
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-continued
Pro Glu Gly Asp Asp Lys Pro Gly Ala Val Gly Lys Val Val Pro Phe
355 360 365
Phe Glu Ala Lys Val Val Asp Leu Asp Thr Gly Lys Thr Leu Gly Val
370 375 380
Asn Gin Arg Gly Glu Leu Cys Val Arg Gly Pro Met lie Met Ser Gly
385 390 395 400
Tyr Val Asn Asn Pro Glu Ala Thr Asn Ala Leu lie Asp Lys Asp Gly
405 410 415
Trp Leu His Ser Gly Asp lie Ala Tyr Trp Asp Glu Asp Glu His Phe
420 425 430
Phe lie Val Asp Arg Leu Lys Ser Leu lie Lys Tyr Lys Gly Tyr Gin
435 440 445
Val Ala Pro Ala Glu Leu Glu Ser lie Leu Leu Gin His Pro Asn lie
450 455 460
Phe Asp Ala Gly Val Ala Gly Leu Pro Asp Asp Asp Ala Gly Glu Leu
465 470 475 480
Pro Ala Ala Val Val Val Leu Glu His Gly Lys Thr Met Thr Glu Lys
485 490 495
Glu lie Val Asp Tyr Val Ala Ser Gin Val Thr Thr Ala Lys Lys Phe
500 505 510
Arg Gly Gly Val Val Phe Val Asp Glu Val Pro Lys Gly Leu Thr Gly
515 520 525
Lys Leu Asp Ala Arg Lys lie Arg Glu lie Leu lie Lys Ala Lys Lys
530 535 540
Gly Gly Lys Ser Lys Leu 
545 550
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The invention claimed is:
1. A modified luciferase which exhibits greater activity in 
the presence of chloroform than wild type luciferase of SEQ 
ID NO: 6 in the presence of chloroform, comprising a 
polypeptide having an amino acid sequence which differs 
from SEQ ID NO: 6 in that serine is replaced by threonine 
at amino acid 239.
2. A modified luciferase which exhibits greater activity in 
the presence of chloroform than wild type luciferase of SEQ 
ID NO: 6 in the presence of chloroform, comprising a 
polypeptide which differs from SEQ ID NO: 6 in that serine 
is replaced by threonine at amino acid 239 and alanine is 
replaced by threonine at amino acid number 532.
3. A modified luciferase which exhibits greater activity in 
the presence of chloroform than wild type luciferase of SEQ 
ID NO: 6 in the presence of chloroform, comprising a 
polypeptide which differs from SEQ ID NO: 6 in that serine 
is replaced by threonine at amino acid 239, alanine is 
replaced by threonine at amino acid number 532 and aspartic 
acid is replaced by tyrosine at amino acid 357.
4. A modified luciferase which exhibits greater activity in 
the presence of chloroform than wild type luciferase (SEQ 
ID NO: 6) in the presence of chloroform, comprising a 
polypeptide having an amino acid sequence which differs
from SEQ ID NO: 6 in that alanine is replaced by threonine 
at amino acid number 532.
5. A polypeptide comprising an amino acid sequence 
selected from the group consisting of SEQ ID NO: 2 and 
SEQ ID NO: 4.
6. The polypeptide of claim 5 wherein the amino acid 
sequence is SEQ ID NO: 2.
7. The polypeptide of claim 5 wherein the amino acid 
45 sequence is SEQ ID NO: 4.
8. A fusion protein comprising the polypeptide of claim 5.
9. A polynucleotide encoding the polypeptide of claim 5.
10. The polynucleotide of claim 9 wherein the amino acid 
sequence is SEQ ID NO: 2.
50 11. The polynucleotide of claim 10 wherein the poly­
nucleotide is SEQ ID NO: 1.
12. The polynucleotide of claim 9 wherein the amino acid 
sequence is SEQ ID NO: 4.
13. The polynucleotide of claim 12 wherein the poly- 
55 nucleotide is SEQ ID NO: 3.
14. A vector comprising the polynucleotide of claim 9.
15. A host cell comprising the vector of claim 14.
